​

HilleVax Stock (NASDAQ:HLVX)

ForecastOwnershipFinancialsChart
HilleVax by TradingView

Previous Close

$1.65

52W Range

$1.34 - $16.30

50D Avg

$1.71

200D Avg

$2.07

Market Cap

$82.73M

Avg Vol (3M)

$191.43K

Beta

0.86

Div Yield

-

HLVX Company Profile

HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

14

IPO Date

Apr 29, 2022

Website

HLVX Performance

HLVX Financial Summary

Dec 24Dec 23Dec 22
Revenue---
Operating Income$-155.29M$-133.34M$-65.11M
Net Income$-147.27M$-123.57M$-257.00M
EBITDA$-155.29M$-132.47M$-65.11M
Basic EPS$-3.00$-3.04$-6.83
Diluted EPS$-3.00$-3.04$-6.83

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

TickerCompany
MLYSMineralys Therapeutics, Inc.
PHVSPharvaris N.V.
CSBRChampions Oncology, Inc.
MOLNMolecular Partners AG
CCCCC4 Therapeutics, Inc.
IPSCCentury Therapeutics, Inc.
MNOVMediciNova, Inc.
PMVPPMV Pharmaceuticals, Inc.
OPTOpthea Limited
STROSutro Biopharma, Inc.
GLUEMonte Rosa Therapeutics, Inc.
EWTXEdgewise Therapeutics, Inc.
CNTACentessa Pharmaceuticals plc
VIGLVigil Neuroscience, Inc.
CGEMCullinan Oncology, Inc.
TRDAEntrada Therapeutics, Inc.
PEPGPepGen Inc.
STTKShattuck Labs, Inc.